MyOme’s Post

Accelerate patient access to therapeutic solutions with CENTOGENE. You may already know that we offer custom testing programs to diagnose rare and neurodegenerative disease patients accurately, with best-in-class genomic testing. But what sets us apart is our CENTOGENE Biodatabank, with its integrated multiomic data repository of >800,000 individuals, and our own expertise of >15 years in bioinformatics, genetics, and multiomic/phenotypic analysis. This enables genetic and HPO profiling of patients, finding patients based on disease profiles, outreach to >30,000 physicians in our global HCP network, and expert support in local languages from our staff of over 60 nationalities. CENTOGENE is committed to being your partner – contact us to gain access to our expert team! marcin.kaleba@centogene.com #Collaboration #Pharma #Partnership #Diagnostics #RareDisease #Neurodegenerative #Patients #Physicians #CRO

A Complete Guide to “𝐇𝐋𝐀 𝐓𝐲𝐩𝐢𝐧𝐠”[PDF-Guide] ➤ 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐆𝐫𝐚𝐛 𝐏𝐃𝐅 : https://lnkd.in/dCpGMyXn #HLATyping, or #HumanLeukocyteAntigentyping, is a crucial genetic testing method used to determine an individual's HLA genotype. HLA genes play a significant role in the #immune system and are essential for #organtransplantation, as well as in the #diagnosis and treatment of #autoimmunediseases and certain genetic disorders. ➤𝐓𝐫𝐞𝐧𝐝𝐬: 1.      𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: The development of high-throughput #NGStechnologies has improved the speed and accuracy of HLA typing. 2.      𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞: HLA typing is becoming increasingly important in the field of personalized medicine, where #treatment plans are tailored to an individual's genetic makeup. 3.      𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭𝐬: As #healthcare infrastructure improves in emerging #economies, the demand for HLA typing is expected to rise. ➤𝑲𝒆𝒚 𝑷𝒍𝒂𝒚𝒆𝒓𝒔: Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Qiagen N.V., Genome Diagnostics B.V., Illumina, Inc, CareDx , Immucor Inc, TBG Diagnostics Limited ➤ 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐁𝐥𝐨𝐠: https://lnkd.in/dxkHRTh2 #HLATyping #Immunogenetics #Transplantation #HLAMatching #GeneticCompatibility #HLAAlleles #HLAAnalysis #HLALaboratory #HLAResearch #HLARegistry #TissueMatching #HLAInnovation #DonorMatching #HLAStudies #HLATest

Genetics is the new frontier of healthcare, and #Genes2Me is your one-stop solution for next generation sequencing tools. We provide a whole range of focused 27+ CE-IVD marked #NGS Clinical Panels compatible with #Illumina, Thermofisher and MGI platforms. The panels are designed for accurate #diagnosis of a variety of #genetic and somatic #cancers, cardiovascular, respiratory and neurological disorders which aid in the prevention as well as timely treatment of the patient. Our NGS clinical #panels are complemented with cloud-based automated data analysis #software called #CliSeq Interpreter. https://lnkd.in/gmvpbZz2 #nextgenerationsequencing #bioinformatics #genomics #ngspanels #analysis #sequencing #research #liquidbiopsy #ngsanalysis #genomics #biotech #biotechnology #bioinformatics #yearsofexcellence #data #bioindia #dna #rna #liquidbiopsy #sequencing #genome #genomeanalysis #molecularbiology #g2m

#HighlyCitedPapers 📝 Biomarkers as Predictive Factors of Anti-VEGF Response — Bobadilla et al. In this paper, the authors aimed to discuss the great controversy between genetic, proteomic and metabolomic studies carried out in age-related macular degeneration ranibizumab-treated patients, and propose that genomic, proteomic and/or metabolomic markers could be used not alone but in combination with other methods to identify patients with a poor response to anti-VEGF treatment to establish patient-specific treatment plans. Full text is available 👇 https://lnkd.in/dx39dDdd #medicine #health #research #science

CENTOGENE testing programs are capable of bringing sponsors so much more than diagnostics. With our multiomic and bioinformatics expertise, our expert disease profiling makes patient diagnosis much more accurate. Local support makes physician outreach and patient testing that much easier. Contact us to find out how you can access CENTOGENE's capabilities! #sponsoredtesting #diagnostics #patienttesting #multiomictesting

Taking Vitamin A to improve your eyesight is not always recommended. Normally, our body uses vitamin A to make retinal cells that are important for central vision. The fatty by-products are then cleared by a protein called ABCA4. For patients with Stargardt disease, a rare genetic mutation in the ABCA4 gene stops the protein from doing its job. The result is a buildup of yellowish fatty clumps that can lead to loss of central vision and night blindness. Beverly Mok believes that RNA editing to correct a defective ABCA4 could potentially treat Stargardt – which currently has no known treatment. Prior to joining IMCB, Beverly amassed experience in nucleic acid editing technologies during her time at Harvard University with Prof David Liu. Beverly brings this expertise to her strong collaboration with clinician-scientist Xinyi Su to expand the toolbox for therapeutic RNA editing of Stargardt. Like many emerging young scientists at IMCB, Beverly is supported by a Young Investigator Research Grant awarded by the The National Medical Research Council (NMRC). Come find out how IMCB brings researchers and clinicians together to develop better treatments and improve human health! #IMCBastar #IMCBtalents #IMCBscience #RNAediting #geneediting #stargardtdisease

𝐂𝐚𝐫𝐫𝐢𝐞𝐫 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 $𝟓.𝟒 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟖 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/d5mfDrVB The size of global carrier screening market in terms of revenue was estimated to be worth $2.2 Billion in 2023 and is poised to reach $5.4 Billion by 2028, growing at a CAGR of 19.7% from 2023 to 2028. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Good Start Genetics Bioarray Genetic Diagnosis The Allied Group. IGENOMIX UK Picture Genetics Repromed South Genetics, Inc. Jetanin Hospital Neoscreen Medical Ltd Advanced Testing in Clinical Genetics Lumi Health AU TAGmedica Miragenex CellGenetics Noor Thalassemia Foundation #CarrierScreening, #GeneticTesting, #HealthcareInnovation, #PrenatalCare, #MedicalResearch #carrierscreeningmarket

News from BGV (BioGeneration Ventures) portfolio company, AZAFAROS B.V. Azafaros prepares to unveil data from the PRONTO study at the 20th annual WORLDSymposium™, focusing on GM1 and GM2 gangliosidoses. With four posters showcasing baseline data from the natural history study, Azafaros is shedding light on the intricacies of these rare diseases. The company is set to reveal the study design for the Phase 2 RAINBOW study, exploring the potential of their lead product, nizubaglustat, in patients with GM2 gangliosidosis and Niemann-Pick disease type C (NPC). Additionally, the results of the Phase 1 first-in-human study, examining the safety of nizubaglustat in healthy volunteers, have been recently published in the prestigious Molecular Genetics and Metabolism journal. Read more by clicking the link below. #Azafaros #RareDiseases #WORLDSymposium #MedicalInnovation #BGVPortfolioCompany #lifesciences #biotech

🥷,🧬 Researching "Stealth" LNPs to avoid triggering immune responses? Get inspired by this great pre-print of a multi group collaboration from University of Pennsylvania on bioRxiv. While #mRNA #LNPs products are on the market, #pDNA delivery via LNPs is still extremely challenging due to inflammatory responses primarily caused by cGAS-STING pathway activation. This pre-print (https://lnkd.in/dZGEXzAK) describes how nitro-oleic acid (NOA) as component of pDNA-loaded LNPs (NOA-pDNA-LNPs) ameliorates inflammatory responses in vivo (mouse). The teams conducted an LNP formulation screen, which drove up the expression 50-fold in vitro. This expands the genetic medicine toolbox and helps leveraging DNA’s benefits of long-term and promoter-controlled expression. Looking forward to seeing this published soon, amazing work, well done Manthan Patel, Sachchidanand Tiwari, Ph.D., Yufei (Sophie) Wang, Sarah O'Neill, Jichuan Wu, Serena Omo-Lamai, Carolann Espy, Liam Chase, Aparajeeta Majumder, Evan Hoffman, Anita Shah, András Sárközy, Jeremy Katzen, Norbert Pardi, Jake Brenner.

🔬🌟 NalaGenetics Shines at the 4th BCM-CUHK-NUS Joint Symposium in Clinical Genetics 🌏💡 We're thrilled to be an active participant at the esteemed "4th BCM-CUHK-NUS Joint Symposium in Clinical Genetics," hosted in Singapore. At this incredible opportunity, NalaGenetics showcases our cutting-edge Clinical Decision Support software, along with our pioneering nutrigenetics and pharmacogenomics services. One of the highlights of our showcase is the introduction of our flexible-depth genome sequencing capabilities. This innovative approach perfectly balances cost-efficiency with remarkable accuracy, presenting a valuable resource for promoting research collaborations and propelling genetic research initiatives forward. Stay tuned for more updates as we continue to drive innovation in the field of genetics and contribute to advancements in healthcare and research! 🚀🧬 National University of Singapore The Chinese University of Hong Kong Baylor College of Medicine #NalaGenetics #NationalUniversityoofSingapore #TheChineseUniversityofHongKong #BaylorCollegeofMedicine #GeneticResearch #ClinicalGenetics #InnovationInHealthcare